REPL vs XYL · $825.7M cap vs P/E 27, rev $8.56B
Replimune Group Inc (REPL) versus Xylem Inc (XYL) — a side-by-side from cached financials, not a winner call.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Xylem Inc (XYL) is a specialty industrial machinery company listed on NYSE.
REPL does not have a complete income-statement cache yet.
Latest reported XYL revenue for 2024-12-31 was $8.56B. Net income was $890.0M. Revenue was up 16.3% from 2023-12-31 to 2024-12-31. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
REPL currently screens at market cap $825.7M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
Not investment advice. Open the REPL and XYL stock pages for the full models.
Not investment advice.